Blood-based monitoring

Detect progression early after cancer treatment initiation.

Is the therapy


Best decision earlier

DetermaCNI™ testing detects progression early, often after one cycle of treatment, and requires NO Tissue – saving time and significant costs.1

Non-Surgical Candidates

Typically, patients with advanced cancer

  • Evaluating early phase therapies
  • Targeted therapies
  • ICI or novel IO combinations

Resistance and progression

Only a fraction of patients being treated for cancer
respond to treatment.2

Identifying progression early allows physicians to change the course of therapy quickly when time is of the essence. For pharmaceutical companies conducting clinical trials, DetermaCNI can de-risk clinical trials by identifying non-responders early.3

In published studies, DetermaCNI identified progressors early and with high accuracy. Patients with elevated DetermaCNI scores were more than 95% likely to experience clinical progression (>95% PPV).

Sample Patient Reports

DetermaCNI is the only solution that checks all of the boxes

How our test works


  1. Weiss GJ, Beck J, Braun DP, et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clin Cancer Res. 2017;23(17):5074-5081. doi:10.1158/1078-0432.CCR-17-0231
  2. Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma [published correction appears in Invest New Drugs. 2019 Aug;37(4):797]. Invest New Drugs. 2018;36(1):96-102. doi:10.1007/s10637-017-0525-1
  3. Schirmer MA, Beck J, Leu M, et al. Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. Clin Chem. 2018;64(6):959-970. doi:10.1373/clinchem.2017.285668
  4. Schütz E, Akbari MR, Beck J, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem. 2015;61(1):239-248. doi:10.1373/clinchem.2014.226571